API Manufacturing facilities
The API manufacturing division is engaging in high-quality synthetic API production using the state of the art facilities in strict compliance with GMP regulations. The API plant consists of 3 separate buildings where are the Cephalosporin plant(API), cytotoxic anticancer plant(API&FDF), and General API building(API & Intermediates) complying with international GMP regulation. In particular, it has the best production infrastructure such as Building Management System (BMS) and an automated warehouse to create an optimal pharmaceutical production environment. These systems contribute to Jeil Pharm to be one of the global pharmaceutical companies offering innovative healthcare solution to the market
Dedicated manufacturing buildings
Cephalosporins : SUS, G/L and Hastelloy reactor, Freeze dryer . STS Reactor
Cytotoxic Anti-Cancer : G/L reactor
General API : High Pressure SUS Reactor, G/L reactor
2019.7 Registered Master File of Cinacalcet in Japan (PMDA)
2017.10 Registered Master File of Meropenem in Japan (PMDA)
2017.04 Received CEP/COS for Cefpodoxime Proxetile(EDQM, Europe)
2012.07 Enlargement of Sterile Crystallization capacity for Carbapenems
2012.03 Constructed dedicated facility for Cephalosporin and Cytotoxic anticancer
2011.10 Enlargement of Sterile Lyophilization capacity for Cephalosporin
2011.08 Launched Meropenem Inj. in Korea/td>
2010.10 Started supplying Carbapenem APIs to its originator in Japan
2010.02 Succeeded in commercial manufacturing Sterile Flomoxef sodium
2009.05 Obtained GMP approval for sterile APIs by PMDA in Japan
2008.07 Received EDQM GMP audit for sterile APIs
2007.02 Started exporting Imipenem/Cilastatin (FDF / APIs)
2006.01 Started producing Panipenem/Betamipron (Powder formulation)
2005.01 Started producing Cilapenem (Imipenem/Cilastatin) (Powder formulation)
2004.11 Started producing Cefditoren Pivoxil (Oral antibiotic)
2003.03 Started exporting Injection in vial forms
2003.01 Started exporting Cefditore Pivoxil(API)
2002.07 Constructed a plant for synthesis of sterile and antibiotic APIs
2001.06 Started exporting Piperacillin Acid to Toyama Chemical in Japan
2001.02 Started producing Epinastine HCl
2000.03 Started producing Cefteram Pivoxil
1999.05 Obtained BGMP for all product (general, special, sterile)
1998.04 Started OEM production for the sterile lyophilized product (Vancomycin)
1998.02 Started exporting Sulbenicillin Sodium to Takeda Pharm in Japan
Major Products
Cephalosporin Cefditoren Pivoxil/ Cefteram Pivoxil / Cefcapene Pivoxil/ Flomoxef soduim/ Latamoxef soduim
Cytotoxic Irinotecan HCl/ Pemetrexed Sodium
General API Epinastine HCl/ Rosuvastatin Calcium/ Entecavir monohydrate/ Sarpogrelate HCl/ Clopidogrel Bisulfate/ Adefovir dipivoxil/ Bosentan hydrate